ArticleCureus2025
Residual Eosinophilic Inflammation of Sinonasal Mucosa Under the Maintenance Phase of Eosinophilic Granulomatosis With Polyangiitis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveComorbid chronic rhinosinusitis (CRS) can be observed during the maintenance phase of eosinophilic granulomatosis with polyangiitis (EGPA), particularly during the tapering of oral corticosteroid (OCS) dosages, even when treated with mepolizumab (MPZ). Control of the comorbid CRS might be key for the remission of EGPA with lower OCS dosages, but the clinical features remain unclear. This study retrospectively investigated the clinical features of comorbid CRS during the EGPA maintenance phase.
methods11 patients were included in this study. Clinical data, including details of the EGPA treatment, were analyzed. The histopathological eosinophilic count was assessed to determine the phenotype of the comorbid CRS. To assess the severity, the criteria defining primary eosinophilic CRS (eCRS) were used: a histopathological eosinophilic count ≥10 per high-power field.
resultsThe median SNOT-22 score (interquartile range [IQR]) was 23 (15-55), and six (55%) patients were classified into the moderate/severe category of SNOT-22 stratification. Nine (82%) patients had nasal polyps (NPs). Six (55%), seven (64%), six (55%), and two (18%) patients received inhaled corticosteroids, MPZ, immunosuppressants, and nasal corticosteroids, respectively. All patients received OCS, and the median value (IQR) was 4 (1-5) mg/day. In absolute eosinophil count (AEC) of blood tests, one patient (9%) exhibited blood eosinophilia (AEC ≥500/μL), and the median value (IQR) was 52 (29-371) /μL. In the histopathological eosinophilic count of the sinonasal mucosa, 10 (91%) patients met the diagnostic criteria for primary eCRS, with a median value (IQR) of 136 (78-134) cells/high-power field.
conclusionsNPs with eosinophilic inflammation without blood eosinophilia can be observed during the maintenance phase of EGPA. Current treatments, including MPZ for EGPA and its comorbidities, may be insufficient to control comorbid CRS. Endotypic investigation of the sinonasal mucosa is required to elucidate its pathophysiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.